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ABSTRACT 
 
This study focused on reprogramming of energy metabolism of cancer cells, since most 
cancer and proliferating cells have been shown to display a metabolic shift by displaying 
increased dependence on glycolysis and reduced oxidative phosphorylation (OXPHOS) for 
energy. Dichloroacetate (DCA) and Methyl pyruvate (MP) were used to attempt the reversal 
of the metabolic program of THP-1 cells. Flow cytometry was used to determine the mode of 
cell death and to analyse the changes in cell cycle.  
In this study, an overexpression of TLR4 was observed in THP-1 cells treated with 5ng/ml of 
lipopolysaccharides (LPS). Further analysis of cell death showed that MP and DCA-treated 
cells resulted to minimal induction of apoptotic cell death. This suggests that the 2 drugs (MP 
and DCA) cause cell death via apoptosis. Furthermore, LPS treated cells (infected cancer 
cells) showed an increase in glycolysis (Warburg effect). This study has shown that indeed 
treatment with drugs such as MP and DCA was effective in reversing the glycolytic 
phenotype of THP-1 cells, resulting in cell death via apoptosis by boosting OXPHOS. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Overview of cancer 
According to statistics from GLOBOCAN, cancer is a growing public health 
problem (International Agency for Research on Cancer and World Health 
Organization 2014), with more than 14 million cases newly diagnosed cancer 
patients in 2012 and about 8 million of those patients lived in the less developed 
regions of the world. Statistics for the year 2012 indicate that cancer killed 
slightly more than 8 million people and 5.3 million cases were reported in less 
developed regions. It is estimated that nearly 50% of all new cancer patients will 
die within 12 months of diagnosis as the five-year survival rates for all cancers in 
both developing and developed countries have been found to range from 30 to 
60% (Kaur and Mohanti, 2011).  
Cancer has been defined as a cell growth disorder, that can be characterised by 
proliferation of genetically dysfunctional cells (Raven and Johnson, 1996). When 
cells continue to replicate in an uncontrolled manner, they lead to a cluster of cells 
known as a tumour or a neoplasm. When the neoplastic cells remain clustered 
together, they are found to be non-cancerous and can be removed with surgery. 
Cancerous cells become harmful when they invade the surrounding tissue and 
break away from the tumour. They enter the blood or lymph vessels and form 
secondary tumours known as metastases in other parts of the body. Cancers are 
classified according to the tissue and cell type from which they develop. 
Carcinomas develop from epithelial cells, whereas cancers of the connective 
tissue or muscle cells are referred to as sarcomas. Other cancers arising from 
haemopoietic cells, known as leukaemia, and nervous tissue do not fall into these 
categories (Raven and Johnson, 1996). 
Leukemia is a type of cancer reported to arise from the dysfunction of the 
hematopoietic cells in bone marrow, arising from inequalities of intracellular 
DNA molecules. The excessive formation of immature leucocytes obstructs 
numerous functions of the bone marrow and as a result the count of normal blood 
cells decreases significantly. Leukemia cancer was found to be the most prevalent 
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while its mortality as a malignant disorder ranks first when compared to other 
pediatric cancers. Leukemia cells can migrate to other parts of the body including 
central nervous system, spleen, lymph nodes, liver (Mardiros et al., 2013). 
Leukemia can be classified into four major classes; lymphoblastic leukemia, 
chronic lymphocytic leukemia, chronic myeloid leukemia and acute myeloid 
leukemia (Vardiman et al., 2009). Current treatment for leukemia involves 
therapeutic options such as chemotherapy, radiotherapy or combination of both. In 
some cases, bone marrow and targeted therapy is required. Most cases of 
leukemia are treated using chemotherapeutic drugs that are combined into a 
multidrug dose therapy, treatment has proven unsuccessful (Hoffbrand et al., 
2006). The drug resistance indicates the non-susceptible nature of leukemia cells 
towards chemotherapeutic drugs (Badura et al., 2013). Taken together, targeting 
the energy metabolism of cancer cells might provide a promising avenue for 
cancer therapy. 
Cancer cells display an increased use of glucose via glycolysis as a cellular 
resource, (Warburg effect). In contrary to normal cells, cancer cells often display 
dysregulated metabolism and take advantage of the abundant resources available 
within the body. Intermediates produced through glycolysis are diverted to 
biosynthetic pathways that are necessary to produce the building blocks to keep 
up with these highly proliferative cells. Carbon from glucose is used for the 
synthesis of nucleotides and amino acids. These metabolic changes observed in 
cancer allow readily available resources to be converted into biomass in an 
efficient manner. This metabolic shift releases cells from the typical restraints on 
growth, and provides a potential way to distinguish them from healthy cells and 
this allows for treatments that may be selective for cancerous cells. 
1.2 Metabolic reprogramming in cancer and immune cells 
In non-proliferative cells, glucose is metabolized to pyruvate, an end product of 
glycolysis that is converted to Acetyl-CoA. Acetyl-CoA then enters the TCA 
cycle and further down into the electron transport chain (Warburg et al., 1927). 
Within the TCA cycle and OXPHOS, the acetyl CoA is oxidized to carbon 
dioxide and water, generating 36 ATP molecules. In contrast, most cancer and 
proliferating cells have been shown to display a metabolic shift by displaying 
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dependence on glycolysis as opposed to oxidative phosphorylation (OXPHOS) for 
energy. Cancer cells depend primarily on the glycolytic pathway for production of 
energy in the form of ATP and for the synthesis of metabolic intermediates to 
shunt into biosynthetic pathways. This phenomenon is commonly known as the 
Warburg effect (Warburg, 1956). They utilize multiple mechanisms that help 
them reprogram their metabolism. Cancer cells reprogram their metabolic 
pathways to ensure ATP is readily available for nutrient synthesis and 
proliferation. Although glycolysis only yields 2 ATPS while OXPHOS 36 ATPs, 
cancer cells still prefer the glycolytic pathway as it is faster, giving them a 
constant supply of ATP. Constantly proliferating cells like cancers require 
bioenergetic and biosynthetic activities, which are redirected towards nucleic 
acids, fatty acids and amino acids production to ensure the cell proliferation 
(DeBerardinis et al. 2008). The metabolic switch observed in cancer cells is 
facilitated by oncogenes and tumour suppressors (Vogelstein and Kinzler, 2004). 
This is achieved by maintaining high rates of glycolysis, slowing glycolytic end-
product entry into OXPHOS and utilizing TCA intermediates for biosynthetic 
precursors.   
 Upon stimulation of the innate immune cells by agonists such as 
Lipopolysaccharide (LPS), innate immune cells also rewire their metabolism in a 
manner similar to that observed in cancer cells. Innate immune cells display a 
shift in metabolism by showing an increase in glycolysis and decrease in 
OXPHOS (Krawczyk et al., 2010; West et al., 2011).  
1.3 Cellular respiration  
Glycolysis 
Glycolysis involves several enzymes in the 10-step reaction, where some of the 
glycolytic intermediates serve as carbon sources for the synthesis of 
macromolecules precursors. During glycolysis, glucose is transported by glucose 
transporters (GLUT) into the cell. Inside the cell, glucose completely oxidized in 
order to produce energy in the form of adenine triphosphate (ATP). During 
glycolysis (which occurs in the cytoplasm of the cell), glucose (a six-carbon 
molecule) is converted into two 3-carbon molecules of pyruvate and ATP is 
formed. This is a ten-step reaction that involves multiple enzymes. Two ATP 
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molecules, two pyruvate molecules and two electron carrying molecules of 
NADH are produced per glucose molecule (Figure 1.6). 
Tricarboxylic acid cycle (TCA) 
Each pyruvate molecule is converted to Acetyl CoA, which then moves into the 
mitochondria. Acetyl CoA binds to oxaloacetate through a series of enzymic 
reaction. This yields the production of NADH, FADH, ATP and carbon dioxide 
(Figure 1.6). 
Electron transport chain 
Occurs in the mitochondria, which is responsible for providing the majority of 
cellular ATP through a series of membrane-bound carriers that pass electrons 
from one to another (Boneh, 2006). OXPHOS is comprised of five protein 
complexes that located in the inner mitochondrial membrane. These complexes (I-
IV) are responsible for transferring electrons. This energy transfer allows 
complexes to pump electrons throughout the inter mitochondrial membrane space, 
leading to the generation of a proton gradient. The proton gradient is used by an 
enzyme called ATP synthase to mechanically generate ATP (Collins et al., 2002). 
Reactive oxygen species 
Reactive oxygen species (ROS) must be present within a certain range for a 
normal cellular function to occur, therefore it is important that production of ROS 
is controlled. ROS include a variety of molecules and free radicals that are derived 
from molecular oxygen such as superoxide anion and peroxide radical. Non-
radical species such as hydrogen peroxide (H2O2) are also found to be reactive 
(Balaban et al., 2005). ROS can be produced by NADH oxidase, as well as by the 
mitochondria as a by-product of OXPHOS. Production of ROS can also be 
triggered by external agents. Excessive production of ROS can be harmful to 
human cells as they induce DNA damage (Kowaltowski et al., 2009).  
1.4 Hypoxia and HIF-1α role in immunity, carcinogenesis and 
metabolism 
Hypoxia, is a characteristic of many cancer cells and occurs because of enhanced 
cell proliferation. It has been shown to be involved in metabolic reprogramming 
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in some cancer cell lines. For example, the contribution of OXPHOS to ATP 
production by HeLa and MCF cells drops by 50% when the cells are exposed to 
hypoxic environments (Rodríguez-Enríquez et al., 2010). However, other 
mechanisms have been found to be involved in metabolic reprogramming of 
cancer cells in normoxic microenvironments. This observation was made in lung 
cancers which are found in microenvironments of high oxygen tension but still 
display high glycolysis (Elstrom et al., 2004; Christofk et al., 2008), which 
confirms that metabolic reprogramming can be triggered by hypoxia-independent 
mechanisms. Lipopolysaccharides (LPS) from gram negative bacteria are also 
known to activate the expression of HIF-1α in normoxic microenvironments. In a 
recent study, LPS was shown to induce the expression of HIF-1α in a translation-
dependent manner, mediated by TLR4 and accompanied by an increased 
expression of glycolytic genes such as GLUT1, lactate dehydrogenase and 
phosphoglycerate kinase (Jantsch et al., 2008). In lung cancer cells, HIF-1α drives 
metabolic reprogramming, decreases ROS levels and eases metastatic 
colonization (Zhao et al., 2014). This serves, at least in part as one of the 
mechanisms by which metabolic reprogramming occurs in activated innate 
immune cells and in tumour cells. 
1.5 Lipopolysaccharide (LPS) and neutralization thereof by Polymyxin 
B (PmB) 
LPS is a layer that is found on the cell wall of Gram-negative bacteria. It consists 
of two main parts namely; a polysaccharide part and a lipid part (Figure 1.1). The 
lipid A structure is the one which is responsible for the immune activation of LPS. 
The LPS molecule differ between different gram-negative bacteria and this is why 
some bacteria may be more immunogenic than others (Zughaier et al., 2005).  In 
innate immune cells (upon infection by LPS), free LPS is bound by LPS binding 
protein (LBP) and CD14 and transported to the cell membrane of immune cells, 
such as antigen presenting cells. The complex is recognised by TLR4/MD2 and 
initiates cellular signalling. Lipopolysaccharide is a potent inducer of pro-
inflammatory responses. Activation of cells with LPS has led to the secretion of 
several cytokines and chemokines (Corinti et al., 2001; Verhasselt et al., 1997). 
LPS was used to mimic infection.  
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Figure 1.1: A simplified LPS structure. Schematic diagram showing the lipid A and 
polysaccharide portions of LPS.  An illustration of the three different portions of the 
LPS molecule.  
Antibiotics are naturally found in biological materials in very small quantities. 
They have been evolving from natural sources and many efforts are being done to 
synthesize and develop their relatives holding specific structures. These structures 
are different in their mechanisms of action. Polymyxin B (PmB) was used in this 
project to neutralize LPS by blocking its activity. Polymyxins are antibiotics that 
actively act against gram negative bacteria. The generic name of polymyxins was 
derived from bacteria Bacillus polimyxa (Moyer et al., 1953). Polymyxins B is a 
member of a large class of five polymyxins isolated by Bacillus species. Other 
polymyxins include A, C, D and E, but the only members of class to achieve 
clinical use were from polymyxin B and E because other polymyxins have shown 
to display high toxicity (Falagas et al., 2005). Polymyxins are amphipathic 
antibiotics that act on the external and cytoplasmic membranes. They work 
through a variety of mechanisms including binding to cell envelope components 
such as phospholipids and LPS and thus interferes with cell processes such as 
causing displacement of calcium and magnesium ions, which act as membrane 
stabilizers, this leads to the rupture of the cell membrane which in turn results in 
loss of cellular contents, thus killing bacteria (Storm et al., 1977). The binding 
and inactivation capacity of LPS, has been found to be effective in reducing the 
inflammatory stimulus induced by LPS (Cooperstock, 1974). Removal of LPS and 
inflammatory mediators with polymyxin B, have been proven successful (Shoji, 
2003; Vincent et al., 2005). 
                
      
  
  
 monosaccharides 
O-specific polysaccharide 
 
core polysaccharide 
  
fatty acid 
 
lipid A 
7 
 
1.6 TLR signalling pathway 
The innate immune system is made of Pattern recognition receptors (PRR) which 
are structures that are activated following recognition of pathogen associated 
molecular patterns (PAMPs). PAMPs are unique structures from bacteria, viruses, 
parasites and fungi and damage associated molecular patterns (DAMPs) are 
released endogenously by necrotic cells (Park et al., 2006; Raucci et al., 2007; 
Curtin et al., 2009). PRRs are expressed on various cells of the immune system 
such as monocytes, macrophages, dendritic cells, NK cells, mucosal epithelial and 
endothelial cells (He et al., 2007). There are several families of PRRs, but the best 
characterized are the NOD-like receptor (NLR), RIG-1-like receptor (RLR) and 
Toll-like receptor (TLR) (Liu, 2008). NLRs belong to a large family of cytosolic 
receptors.  They are present inside the cells where they sense intracellular 
bacterial invasion. The best studied NLRs are NOD1 and NOD 2, which 
recognize peptidoglycan of bacterial cell walls (Creagh and O'Neill, 2006). RLRs 
are soluble pathogen recognition receptors that reside in the cytosol of the cells 
where they act as sensors of viral infections (Creagh and O'Neill, 2006). 
This study focused on Toll-like receptors (particularly TLR 4). A family of 
evolutionary conserved PRRs (Roach et al., 2005), was first identified in the fruit 
fly Drosophila, and found to be involved in embryogenesis as well as in 
protection against fungi infection (Lemaitre et al., 1996). Thus far, 11 TLRs have 
been discovered in humans with the first TLR to be discovered being TLR 4 
(Medzhitov et al., 1997). TLRs are classified as type I membrane proteins that 
have an ectodomain with leucine rich repeats and a conserved Toll/Interleukin-1 
(TIR) receptor domain in the cytoplasmic region (O’Neill et al., 2003; Takeda and 
Akira, 2005). In response to their corresponding ligands (such as LPS), TLRs 
initiate a signalling cascade that leads to the expression of transcription factors 
such as nuclear factor-κB (NFκB). NFκB initiates the expression of pro-
inflammatory cytokines and chemokines (Takeda and Akira, 2004). In innate 
immune cells (upon infection by LPS), free LPS is bound by LPS binding protein 
(LBP) and CD14 which is then transported to the cell membrane of immune cells. 
The complex is recognised by TLR4/MD2 and initiates cellular signalling (figure 
1.2). 
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Figure 1.2: Schematic overview of the TLR signalling pathway. Upon stimulation by 
its specific ligand. TLRs recruit adaptor proteins called MyD88 (myeloid differentiation 
factor 88), MAL (MYD88-adaptor-like protein). This leads to the phosphorylation of 
(Inhibitor κ B), which renders NFκB free from its inhibitor. NFκB then translocates to the 
nucleus where it activates inflammatory cytokines and chemokines (Himanshu et al., 
2009). 
1.7 Association of cancer and infection 
The link between cancer and inflammation was made following observations that 
cancer deaths have been associated with infections and chronic inflammation 
(Balkwill and Mantovani, 2001). These infections trigger chronic inflammation 
which is an important factor that contribute in carcinogenesis (Parkin, 2006). 
Chronic inflammation has been associated with certain types of cancer. Examples 
of such includes infection with Helicobacter pylori which has been associated 
with gastric cancer, and inflammatory bowel disease has been associated with 
colon cancer (Koehne and Dubois, 2004; Flossmann and Rothwell, 2007). The 
hallmarks of cancer-related inflammation include the presence of inflammatory 
cells and inflammatory mediators (such as chemokines and cytokines) in tumor 
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tissues similar to that seen in chronic inflammatory responses and tissue repair 
(Borrello, 2005). Toll-like receptor activation by PAMPs has been shown to be 
involved in cancer progression (Huang et al., 2005). Upon infection, cells such as 
macrophages and dendritic cells reprogram themselves in the same manner as 
cancer cells. This metabolic switch is facilitated by interleukin 10 (IL-10) 
(Krawczyk et al., 2010). This creates a link between TLR-signalling and 
carcinogenesis. 
1.8 Mechanisms used by which LPS promotes Warburg metabolism in 
innate immune cells 
The Warburg effect is important in understanding metabolic changes occurring in 
innate immune cells upon activation. To understand the metabolic changes 
occurring in the innate immune cells upon infection, it is important to study the 
Warburg effect.  
1.8.1 Nitric oxide (NO) and metabolic changes in macrophages and 
Dendritic cells 
Upon stimulation of innate immune cells with its agonist LPS, decreased levels of 
OXPHOS and increased levels of glycolysis is observed. Stimulation of these 
cells with LPS have shown to increase the expression of inducible nitric oxide 
synthase (iNOS), which generates nitric oxide (NO), these are reactive nitrogen 
species that can inhibit mitochondrial respiration (Lorsbach et al., 1993; Lu et al., 
1996). Nitric oxide is known to inhibit OXPHOS by nitrosylating iron-sulphur 
proteins such as cytochrome C oxidase and Complex I in the electron transport 
chain, this decreases the activity of the electron transport chain (Drapier and 
Hibbs, 1988; Cleeter et al., 1994).  
1.8.2 Hypoxia-inducible factor-1α (HIF-1α) and glycolysis 
Many cancer cells are exposed to hypoxic conditions where they cannot rely on 
OXPHOS and must modify their metabolism to survive under conditions of 
reduced oxygen tension. HIF-1α is a transcription factor that promotes the switch 
to glycolysis and this allows cancer cells to continue producing ATP under limited 
oxygen conditions (Denko, 2008). Under these circumstances pyruvate, an end 
product of glycolysis, does not feed into the TCA cycle to boost OXPHOS, but is 
instead metabolized to lactate. HIF-1α is responsible for this metabolic switch by 
10 
 
binding to hypoxia response elements in target genes (Semenza et al.,1991; Mole 
et al., 2009). HIF-1α promotes glycolysis by binding to glucose transporter 
GLUT1, which increases the entry of glucose into the cell (Chen et al., 2001). 
HIF-1α also increases the expression of glycolytic enzymes such as lactate 
dehydrogenase (Semenza et al., 1996), this enzyme is responsible for catalysing 
pyruvate into lactate, thereby limiting the entry of pyruvate into the TCA cycle. 
Another enzyme that promotes glycolysis is pyruvate dehydrogenase kinase 
which inhibits pyruvate dehydrogenase (Kim et al., 2006; Papandreou et al., 
2006). This leads to increased levels of glycolysis and decreased levels of 
OXPHOS.  
1.8.3 AMPK and activation of macrophages and DCs 
The principal enzymatic activity of AMP-activated protein kinase (AMPK) is to 
sense energy in macrophages and when stimulated by LPS, the activity of this 
enzyme is decreased (Sag et al., 2008). AMPK has been shown to be active when 
the cellular energy is low and induces the expression of proteins involved in 
OXPHOS. The main function is to conserve energy when it is limited by 
inhibiting anabolic pathways, such as gluconeogenesis, and promoting catabolic 
pathways, such as β-oxidation of fatty acids. Therefore, decreasing the enzymatic 
activity of AMPK increases glycolysis while reducing OXPHOS (Vats et al., 
2006).  
1.9 Apoptosis 
Apoptosis was first described by Kerr, Wyllie and Currie in 1972 as a 
programmed cell death. This is a genetically controlled form of cell death which 
plays an important role in normal tissue development. Apoptosis is involved in 
organogenesis, tissue homeostasis and remodelling (McKenna, 1996). The 
process of apoptosis has been described as an active bio-energy saving cell-
elimination mechanism, which removes aged, unwanted or damaged cells. The 
cellular contents of these cells are phagocytosed by adjacent cells or macrophages 
and these cells are recycled (Vermes et al., 1997). Cancer cells can avoid 
apoptosis and they continue to proliferate, therefore it is important to use drugs 
that induce apoptosis (Debatin, 2004). 
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1.9.1 Morphology of Apoptotic Cells 
Apoptosis is characterised by several distinct morphological changes, including 
blebbing, fragmentation of the nucleus, cell shrinkage, DNA fragmentation and 
lastly cell death (Ouyang et al., 2012). The cytoplasm and nucleus become 
condensed and the chromatin aggregates along the nuclear membrane. 
Degradation at the inter nucleosomal sites of the cellular DNA leads to fragments 
and results in the segmented appearance of the nucleus. The membrane appears to 
be blebbing as the endoplasmic reticulum is transformed. The cell membrane 
becomes rigid due to the cross-linking of the membrane proteins before the cell is 
broken apart into small vesicles called apoptotic bodies. These remain in the 
extracellular space until they are phagocytosed by the neighbouring cells or by the 
macrophages (Vermes et al., 1997; Story and Kodym, 1998; Corfe, 2002; 
Golstein et al, 2003). No damage to the surrounding cells occurs, and no 
inflammatory response is initiated during apoptosis. This change of the cell 
membrane and the altering of the surface hydrophobicity and charge may be 
recognised by the macrophages (Vermes et al, 1997; Corfe, 2002).   
1.9.2 Apoptotic Pathways 
There are two main pathways that control apoptosis, namely the death receptor 
pathway (extrinsic) and mitochondrial pathway (intrinsic), (Wen et al., 2012).  
The presentation of an appropriate ligand for a death receptor causes these to form 
a multi-protein complex called the death-induced signalling complex. This 
complex triggers the direct activation of caspase-8, which belongs to a proteinase 
family known as the caspases. The caspases are thought to be activated and 
specifically during apoptosis. Certain caspases can auto-activate and can then 
activate other caspases and a variety of other cellular substrates. These are 
involved in the breaking down and packaging of the cellular components into 
apoptotic bodies (Vermes et al., 1997; Green and Reed, 1998, Thornberry and 
Lazenbnik, 1998; Li and Yuan, 1999; Adrain and Martin, 2001). 
The second pathway involves intracellular signalling that targets the 
mitochondria, this pathway is regulated by a family of the Bcl-2 protein family. 
These include proapoptotic Bak and Bax, and the anti-apoptotic Bcl-xL and Bcl-2 
proteins. Bcl-xL and Bcl-2 may also be present in the endoplasmic reticulum and 
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the nuclear membrane in some cell types, and often Bax is found in the cytosol. 
Once apoptosis is stimulated, Bax is recruited to the mitochondria where it binds 
to Bak. This complex forms pores in the membrane, allowing the release of 
cytochrome c from the outer mitochondrial membrane and into the cytoplasm and 
the loss of mitochondrial membrane potential. An apoptosome body is formed, 
which is a protein complex consisting of pro-caspase 9 and APAF-1, then binds 
with the released cytochrome c. This leads to the activation of caspase-9, which in 
turn cleaves into active caspase-3 which is responsible for inducing apoptosis 
(Vermes et al., 1997; Green and Reed, 1998, Thornberry and Lazenbnik, 1998; Li 
and Yuan, 1999; Adrian and Martin, 2001; Pommier et al., 2004). 
1.10 Cell cycle 
For an organism to grow and function properly, the cell cycle has to be completed. 
Cell cycle consists of four phases, namely the S-phase whereby the DNA is 
replicated (figure 1.3). The M-phase, two identical chromosomes are distributed 
evenly into two daughter cells (Sherr, 1996). During the G1 phase, preparations of 
DNA synthesis occurs and lastly the G2 phase prepares for cell division or mitosis 
(Vermeulen et al., 2003). Cells in the G0 phase are in a quiescent state, and these 
cells do not divide even though they are still active (Park and Lee, 2003).  
One of the hallmarks of cancer development is the ability of these cells to 
proliferate uncontrollably and cancer cells show mutated genes which play a role 
in the regulation of the cell cycle (Sherr, 1996). p53 is a tumour suppressor 
protein and p16 is a tumour suppressor gene, both of which control the cell cycle 
(Jacks and Weinberg, 1998). 
Cyclin-dependent kinases (CDK’s) are proteins that drive the progression of the 
cell through the stages of the cell cycle (Israels et al., 2000). Activities of the 
CDKs are regulated by cyclins and cyclin dependent kinase (CAK), which is a 
serine/threonine kinase (Nigg, 1996). The cell cycle is regulated by many genes 
and these genes have also been found to control apoptosis (Alenzi, 2004). p53 
plays an important role in the relationship between apoptotic cell death and 
cellular proliferation (Haupt et al., 2003), whose role includes the maintenance of 
genome integrity in the G1-S and G2-M checkpoints of the cell cycle. This is 
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done to detect any DNA damage, thus prevents the progression of aberrant cells 
through the cell cycle (Jin and Levine, 2001). When DNA damage is found during 
the cell cycle checkpoints, regulatory signals that induce cyclin dependent kinase 
inhibitors (CKIs) which stops the cells cycle and repairs the DNA damage (Sherr, 
2000). Mutations in p53 prevents proper functioning of the G1-S and G2-M 
checkpoints, which in turn allows the damaged cells to survive and proliferate 
uncontrollably, this then leads to the promotion of cellular growth (Jin and 
Levine, 2001). 
 
 
Figure 1.3: Schematic representation of the cell cycle phases (G0, G1, S and G2 and 
M) (Vermeulen et al. 2003). 
1.11 Reversal of metabolic reprogramming 
Cancer cells reprogram their metabolism consequently enabling their proliferation 
and migration, thus, reversal of their metabolic processes might be toxic to them 
and inhibit growth. In this study, drugs such as dichloroacetate and methyl 
pyruvate were utilized to reverse the Warburg effect. These drugs are known to 
function in reversing the metabolic reprogramming in cancer cells. 
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Dichloroacetate (DCA)  
Preference of cancer cells to utilize increased levels of glycolysis as a primary 
metabolic pathway for the generation of ATP and reduced OXPHOS levels 
(Warburg effect) has created opportunities for targeting the Warburg effect as a 
potential therapeutic target in cancer therapy. Studies by Bonnet et al., 2007: 
Michelakis et al., 2008 have shown that reversing the Warburg effect in cancer 
cells may result in the induction of apoptosis in cancer cells. Cancer cells rewire 
their metabolism by showing less dependence on OXPHOS, as it gives cancer 
cells the unique ability to avoid apoptotic effects in the mitochondria.  
DCA is a is water-soluble agent with 100% bioavailability when administered 
orally. This is the case because DCA is a very small molecule of about 150 Da 
(Michelakis et al., 2008). DCA is cell permeable and targets cancer cells 
specifically with little or no effect on normal cells (Heshe, 2011). The absorption 
of DCA in the gastrointestinal tract has been found to be good and excretion of 
total DCA has been shown to be less than 1% (Stacpoole et al., 1998).  
Mechanism of action 
DCA (figure 1.4) is a small molecule that has been used for decades for the 
treatment of lactic acidosis (Stacpoole et al., 2008). It is known that cancer cells 
prefer to follow the glycolysis pathway as oppose to the OXPHOS pathway for 
glucose metabolism (Warburg, 1956). Pyruvate dehydrogenase (PDH) is a 
glycolytic enzyme that is responsible for the conversion of pyruvate to acetyl-
CoA, which enters the tricarboxylic acid (TCA) cycle to generate ATP, thus 
promoting OXPHOS. But in cancer cells, the enzymatic activity of PDH is 
inhibited by an enzyme called pyruvate dehydrogenase (PDK) by a process called 
phosphorylation therefore prevents the entry of pyruvate into the TCA cycle 
which in turn results in less OXPHOS and more lactate production (Zhao et al., 
2011; Kato et al., 2007).  The preclinical trials on DCA have shown its 
effectiveness in a variety of cancer cells via induction of apoptosis (Bonnet et al., 
2007; Wong et al., 2008). Treatment of DCA alone is still limited in ongoing 
trials but more effectiveness has been observed in combination therapy (Ishiguro 
et al., 2012). The selective killing mechanism of DCA involves ROS production, 
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loss of mitochondrial membrane potential and apoptotic death (Ayyanathan et al., 
2012). Targeting PDK can result in a balance between OXPHOS and glycolysis. 
This results in the production of ROS that have been shown to be toxic to cancer 
cells. DCA has showed good activity against lung cancer cell line (A549) which 
resulted in increased ROS, preventing tumor growth and promoting apoptosis. 
These findings suggest that DCA would have no effect on normal non-cancerous 
cells (Bonnet et al., 2007). 
 
Figure 1.4: Chemical structure of Dichloroacetate (Michelakis et al., 2008) 
 
Methyl pyruvate (MP) 
In normal cells, the OXPHOS pathway in the mitochondria generates 36 ATP 
molecules per glucose molecule broken down. However, cancer cells favour 
glycolysis which only generates 2 ATP molecules. MP can be used as a strategy 
to target this unique metabolism of cancer cells.   
Methyl pyruvate is a derivative of pyruvate and this drug was used in this study to 
bypass the glycolytic pathway. Methyl pyruvate (MP) is a lipophilic agent in 
nature making it highly permeable to cells.  MP is a favourable substrate than 
pyruvate as it is more stable (Lembert et al., 2001; Düfer et al., 2002). Since 
cancer cells prefer the glycolysis pathway, providing the end-product of this 
pathway might result in a circumvention of this pathway and thus lead to cell 
death. A recent study on A549 and MCF7 cells showed that treatment with 
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exogenous methyl pyruvate led to cell death (Monchusi and Ntwasa, 2017). 
Treatment with methyl pyruvate might boost OXPHOS and thus increases 
apoptosis by mechanisms such as production of ROS in the mitochondria 
(Lembert et al., 2001; Düfer et al., 2002).     
 
1.12 Justification of study 
Generation of ATP through the oxidative phosphorylation in the mitochondria is 
an efficient and preferred metabolic process, which produces far more ATP 
molecules (36 ATP molecules) from a given amount of glucose compared to 
glycolysis. In normal non-proliferating cells, OXPHOS is the preferred pathway 
for energy production and to a lesser extent glycolysis is used as another pathway 
which provides energy for cells. Upon infection however, cells like dendritic cells 
and macrophages tend to reprogram their metabolism in the same manner as the 
cancer cells. Cancer cells and proliferating cells show a deregulated metabolic 
profile by displaying an increased dependence on glycolysis for energy production 
and reduced levels of oxidative phosphorylation OXPHOS (Warburg effect). It is 
hypothesized that upon infection of cancer cells, a further metabolic 
reprogramming is expected. The two drugs (exogenous MP and endogenous 
DCA) to be used in this project have different mechanisms of action, but they 
both boost the mitochondrial OXPHOS. Theoretically it is expected that the 
application of the two drugs will reprogram the metabolism in such a way that 
cells are redirected to increased use of OXPHOS as an energy pathway and to a 
lesser extent, glycolysis (figure 1.5).  
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Figure 1.5: A simplified diagrammatic representation of the metabolic pathways 
(Glycolysis and OXPHOS): an illustration of how the energy metabolism shifts from 
glycolysis to OXPHOS when cells are treated with the two drugs (MP and DCA).  
Pyruvate entry into mitochondria is promoted, therefore an increase in OXPHOS is 
expected. 
 
1.13 Aim 
The aim of this study was to evaluate the molecular basis of metabolic 
reprogramming with a focus on the impact of drugs targeting mitochondrial 
function. 
1.14 Objectives 
 
 (i) To determine the expression of TLR4 in THP-1 cells before and after 
treatment with LPS using RT-PCR. 
(ii) To check the effect of various treatments on the cell cycle and cell 
viability using flow cytometry 
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(iii) To assay metabolic reprogramming by measuring the rate of glycolysis 
and OXPHOS in THP-1 cells before and after treatment with drugs. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Materials 
Materials used in this study are listed under the appendix section. Appendix A has 
a list of chemicals and reagents, supplier and catalogue number. Appendix B 
consists of a list of laboratory equipment, supplier and model number. Appendix 
C, kits used, supplier and catalogue numbers. Lastly, Appendix D consists of a list 
of buffers and their composition.  
2.2 Methods 
This section describes methods (Figure 2.1) used in this study, to obtain the 
results that will be discussed in subsequent chapters. A brief introduction of the 
principle behind each technique is discussed, followed by the protocol of the 
technique. 
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2.2.1 An overview of the methods 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flowchart diagram showing methods used in study. THP-1 cells were 
treated with LPS, DCA, PmB and MP. Following treatments, RNA extraction was 
performed, this was followed by flow cytometry assays and lastly Glycolysis and 
OXPHOS assays were performed.  
THP1 cells were cultured under appropriate conditions and treated with several 
drugs (5 ng/ml LPS (from Escherichia coli), 10 mM DCA, 10µg/ml PmB and 
0.08% MP) at varying time periods. First, total RNA was extracted from cells and 
Tissue Culture 
Treatment with LPS,DCA, PmB & MP 
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Apoptosis & Cell cycle 
assays 
Cell cycle assays 
Reversal of the 
Warburg effect 
using drugs (MP & 
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Agarose gel 
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RT PCR performed to observe expression of TLR4. Second, Flow cytometry was 
performed involving cell cycle and apoptosis detection assays. Lastly, Glycolysis 
and OXPHOS assays were conducted to determine the effect of the drugs on 
cancer metabolism. These assays (apoptosis, cell cycle, glycolysis and OXPHOS) 
were performed in triplicates. 
2.2.2 Cell line 
THP-1 cells are derived from the peripheral blood of a 1-year old child with acute 
monocytic leukaemia. They have fc and C3b receptors and lack surface and 
cytoplasmic immunoglobins. These cells show increased CO2 production on 
phagocytosis and can be differentiated into macrophages-like cells using 
compounds such as PMA.  
2.2.3 Cell culturing routine and treatment 
THP-1 cells were grown in RPMI growth medium supplemented with 10% FBS 
(fetal bovine serum) and 1% antibiotic (penicillin/streptomycin). These cells were 
routinely maintained in a humidified atmosphere at 37 ºC in a 5% CO2 incubator. 
THP-1 cells are a non-adherent cell line and have a doubling time of 
approximately 36-48 hours. These cells were sub-cultured every third day of the 
week by centrifuging cells with old medium 1500 rpm for 5 minutes. Following 
centrifugation, the pellet was resuspended in 1 ml of fresh medium. This was then 
transferred into 9 ml of fresh medium and incubated at 37ºC in a 5% CO2 
incubator.  The cultures were regularly examined using light microscopy (200x) 
for morphological signs of cellular damage.  
2.2.4 Cell counting and viability determination 
Cell counts are important as it helps to monitor growth rates. The cells were 
counted and the viability determined using the trypan blue exclusion test. 
Haematocytometer was used to estimate cell number using a thick glass with 2 
counting chambers (1 on each side). Each of the counting chambers contains 
mirrored surface with 3 x 3 grids of 9 counting squares. Each of the 9 counting 
squares holds a volume of about 10 µl. About 10 µl of the cell suspension was 
transferred to 1 side of the chamber. The cell suspension was allowed to fill the 
entire counting chamber and placed under the microscope to view and count cells. 
All unstained cells in the central square of the grid were counted. The volume of 
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the grid is 104 ml therefore the number of cells per ml could be determined. The 
cells were counted and the viability determined using the trypan blue exclusion 
test. This formula was then used to estimate the number of cells/ml:  
Number of cells/ml = Number of cells in central grid x 104 x dilution factor 
Cells were treated with 5 ng/ml of LPS, 0.08% MP, 10 mM DCA and 10 µg/ml 
PmB in time-dependant analyses. Time periods included 6,12,18 and 24 hours. 
Following treatment, cells were rinsed with about 1 ml PBS. One millilitre of 
trypsin-EDTA or citric saline buffer was added and incubated at 37 ºC (for about 
5-10 minutes, regularly checked the cell progression of cell dissociation). 
Following detachment of cells from the flask, trypsin activity was stopped by 
adding 1 ml of fresh culture medium. This mixture was centrifuged at 1500 rpm 
for 5 minutes, and supernatant discarded. 
2.2.5 Cell cryopreservation and recovery 
At regular intervals cells were removed from the cultures and stored frozen at -
70°C. The cells were allowed to grow to the late log phase. A volume containing 
approximately 2 x 105 cells was removed from the flasks and the cells pelleted by 
centrifuging at 1500 rpm for 5 minutes at 20°C. The medium was discarded and 
the cells resuspended in 1 ml of freezing mixture. A volume of freezing mixture 
consisting of 10% DMSO and 90% FBS was added. The cell suspension was then 
transferred into sterile cryotubes and frozen slowly, wrapped in paper towel at -
20°C overnight and then stored at -70°C until required. The cells were recovered 
from frozen storage by rapidly thawing in a water bath at 37°C. 9 ml of warm 
culture medium was added slowly to the cell solution to reduce osmotic shock. 
Centrifugation (1500 rpm for 5 min at 20°C) was used to remove the freezing 
solution, and the cells were resuspended in 9 ml of fresh culture medium. Cells 
were then placed in a small sterile tissue culture flask and maintained as 
previously described. 
2.2.6 RNA extraction using TRIzol method 
RNA extraction is a basic method that is used in molecular biology to extract 
biological material from the cell. Once extracted from the cell, RNA has shown to 
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have a very short life and is unstable. Therefore, it is important to extract RNA of 
good quality and to also avoid keeping RNA samples for a long period of time. 
The medium containing cells (treated and untreated) was centrifuged at 3000 rpm 
for 3 minutes to obtain pellet. Cells were washed twice with 1X PBS. Attached 
cells (following treatment) were detached using trypsin, centrifuged at 1500 rpm 
for 5 minutes. Into each cell pellet, 500 µl of TRIzol was added to each pellet and 
vortexed for 10 seconds for cell lysis and then kept on ice for 5 minutes. 250 µl of 
chloroform was added and left to stand at room temperature for about 10 minutes. 
The tubes were centrifuged at 12 000 rpm for 15 minutes at 4ºC for phase 
separation. The aqueous phase was removed and placed into newly labelled tubes. 
250 µl of Isopropanol was added into each tube and allowed to stand for 5 
minutes at room temperature. The tubes were centrifuged at 12 000 rpm for 10 
minutes at 4-8ºC and supernatant discarded. 150 µl of ice cold 70 % ethanol was 
then added to the pellet and centrifuged for 5 minutes at 12 000 rpm at 4ºC to 
wash the RNA pellet thoroughly. The supernatant was discarded and pellet 
allowed to air dry for 7- 10 minutes. The tubes were then placed open on the 
heating block for 4 minutes to allow further evaporation of ethanol at 50ºC. To 
dissolve the RNA pellet, 50 µl of nuclease free water was added. The tubes were 
immediately placed on ice and the concentration and quality of RNA determined 
using a Nanodrop. 
2.2.7 Complementary DNA synthesis (Reverse Transcription) 
To perform RT-PCR, the obtained RNA template must first be converted into a 
complementary DNA (cDNA). In this study, this was done from 1 µg of total 
RNA using the ProtoScript cDNA synthesis kit (NEB) according to the 
manufacturer’s instructions. Table 2.1 show volumes of the different reagents 
used to make up the mixture for cDNA synthesis. Cycling conditions used were 
those indicated by the manufacturer.  
 
 
 
24 
 
Table 2.1: cDNA synthesis reagents. 
Components Volume (µl) 
Oligo Dt 1 
d NTP mix 1 
Total RNA  3 
Nuclease Free water 9 
Sub-Total                                              14 
5X SSIV buffer 4 
DTT  1 
Reverse Transcriptase 1 
Total volume 20 
   
2.2.8 Polymerase Chain Reaction (PCR) 
 Polymerase chain reaction (PCR) is a technique used for DNA replication, that 
allows target DNA sequences to be amplified into millions of copies. This 
technique involves the primer mediated enzymatic amplification of DNA. Primer 
sequences were identified and synthesized by Inqaba biotech. The cDNA obtained 
through reverse transcription was used as a template using sequence specific 
primers for the TLR 4 gene. The PCR was performed using Taq 2X master mix. 
Reagents were mixed appropriate (table 2.3) using gene specific primers (table 
2.4). The master mix already contains deoxyribonucleotides, PCR buffer, MgCl2 
and Taq Polymerase.  PCR conditions are shown in table 2.2.  
Table 2.2: PCR cycling conditions and time spent per cycle. 
STEP TEMPERATURE TIME 
Initial Denaturation 95ºC 30 secs 
 
PCR cycles (30) 
95ºC 
45-68ºC 
68ºC 
15-30 secs 
15-60 secs 
1 min 
Final Extension 68ºC 5 mins 
Hold 4ºC - 
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Table 2.3: PCR 50 µl reaction mixture 
Component  50 µl Reaction 
100 µM Forward Primer 0.5 µl 
100 µM Reverse Primer 0.5 µl 
Template DNA 3 µl 
Taq 2X Master Mix 25 µl 
Nuclease free water 21 µl 
 
Table 2.4: Primers used for TLR 4 mRNA expression.   
TLR Forward primer Reverse primer 
GAPD
H 
5' GAAGGTGAAGGTCGGAGTC 
3' 
5' 
GAAGATGGTGATGGGATTT
C 3' 
TLR 4 5'CCAGTGAGGATGATGCCAGA
AT 3' 
5'GCCATGGCTGGGATCAGA
GT 3' 
 
2.2.9 Agarose gel electrophoresis 
The principle of agarose gel electrophoresis involves separation of nucleic acids 
according to their size using an electric field. Whereby negatively charged 
molecules migrate towards the anode (positive) side. This migration is determined 
by molecular weight, small molecules migrate faster than large molecules. During 
this technique the DNA fragments can be visualized by staining the gel with 
ethidium bromide, which is a dye that intercalates between bases of DNA and 
illuminates the gel under UV light source. About 1g of agarose powder (1% 
agarose gel) was dissolved in 50ml of 1x TAE buffer and heated until the agarose 
was completely dissolved in TAE. This mixture was further cooled to about 50°C 
and 3 µl (0.8 mg/ml) of ethidium bromide added. Mixture was poured onto a 
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casting tray, placed a comb and allowed the gel to solidify. Once solidified, the 
comb was carefully removed and gel placed inside a tank containing 1x TAE 
buffer. The samples were loaded into individual wells, with the first well used for 
a DNA marker, connected the tank to a power supply and ran the samples at 90 
volts for about 45 minutes. The gel was then visualized under the Bio-Rad Gel 
doc system.  
2.2.10 Flow cytometry 
Flow cytometry is a technique that measures and analyses physical properties of 
cells as they flow in a fluid medium through a laser beam. Measurements include 
size, granularity, and fluorescence (Brown and Wittwer, 2000). In this study, flow 
cytometry was used to assess apoptosis, necrosis and cell cycle analyses 
following treatment with LPS, PmB, DCA and MP. For all drug treatments, cells 
were seeded at a density of 2 x 105 cells/ml in 6-well plates. Drugs were added in 
a time-dependant manner at 6,12,18 and 24 hours respectively and cells were 
incubated under culturing conditions mentioned above. 
Phosphatidyl serine (PS) is a cell membrane phospholipid that plays an important 
role in cell cycle signalling. During the early phases of apoptosis, PS which is 
embedded within the plasma membrane of live cells becomes translocated to the 
external surface of the cell membrane. The externalisation of PS is used as a 
marker of early apoptosis. Annexin V is a calcium ion-dependent protein that has 
a high binding affinity for PS. Annexin V coupled to the green fluorescent dye, 
FITC can be used to assess the level of apoptosis using a flow cytometer 
(Koopman et al., 1994). During necrosis cell death, the plasma membrane 
integrity becomes compromised which results in the exposure of DNA. The 
exposure of DNA is taken advantage of by the DNA-binding dye, propidium 
iodide, as a marker of necrosis.  
Cell cycle assay 
Cell cycle analysis is achieved by using fluorescent nucleic acid dyes such as PI 
(Propidium iodide). PI make use of the fact that DNA contents change as the cell 
progresses from the G1, S and G2 phases of the cell cycle. Cells that are in the S-
phase of the cell cycle have more DNA than those in the G1. While G2 cells have 
27 
 
approximately doubled the amount of DNA found in G1 cells. For cell cycle 
analysis, cellular DNA content is measured using the DNA-binding dye, PI. PI 
intercalates into the helical structure of DNA. The amount of fluorescence yield 
of PI is directly proportional to the amount of DNA present within the cell 
(Brown and Wittwer, 2000). This makes it easy to detect cells that have 
undergone growth arrest at any phase of the cell cycle. 
Cells were harvested by centrifugation at 1500 rpm for 5 minutes. Pellet formed 
was washed twice with PBS (to remove the medium). The cells were then fixed. 
Fixation of the cells was done using 70% (v/v) ethanol. Ethanol is a dehydrating 
fixative agent which also permeabilizes the cells to allow for the binding of PI to 
DNA. The cells were treated and harvested with about 1 ml trypsin. The cells 
were pelleted by centrifugation at 1500 rpm for 10 minutes and cell pellet was 
carefully resuspended in 1 ml of PBS in a 1.5 ml eppendorf tube. The mixture 
was centrifuged for 5 minutes at 5000 rpm and the pellet was resuspended in 300 
μl of PBS. Seventy microliters of 100% ethanol (pre-chilled at -20ºC) was added 
to each sample and mixed by inverting the tube 5 times. The cell suspension was 
centrifuged at 5000 rpm for 5 minutes, after which the supernatant was removed. 
The pellet was then washed twice with 1 ml of PBS, followed by centrifuging at 
1500 rpm for 7 minutes. The PBS supernatant was discarded, and pellet 
resuspended in 300 μl of PI containing RNase and vortexed for 30 seconds. The 
cell suspension was then incubated in the dark for 30 min, after which cell cycle 
analysis were done at 488 nm using the BD Accuri C6 flow cytometer. 
Apoptosis assay 
To ascertain whether the cell death observed is by apoptosis and not necrosis, cell 
viability assays were performed using flow cytometry. Healthy cells have an 
intact plasma membrane while apoptotic cells display loss of plasma membrane. 
In early apoptotic cells, the membrane phospholipid phosphatidyl serine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane, thereby 
exposing PS to the external cellular environment. Annexin V is a 35-36 kDa Ca2+ 
dependent phospholipid-binding protein that has a high affinity for PS and binds 
to the exposed PS. 
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 Staining with Annexin V is used in conjugation with dyes such as propidium 
iodide (PI) to allow identification of early apoptotic cells (PI negative, FITC 
Annexin V positive). Viable cells with intact membrane cannot bind PI while 
damaged cells can. Viable cells are both Annexin V and PI negative. Cells that 
are in early apoptosis are considered Annexin V positive and PI negative, and 
cells that are in late apoptosis are both Annexin V and PI positive.  
 
Following treatments with apoptosis-inducing agents/drugs (MP and DCA) for 24 
hours, the culture media was collected from the 6 well plates and centrifuged at 
1500 rpm for 5 minutes to collect pellets. Cell pellets were then washed in 600 µl 
cold PBS and centrifuged at 1800 rpm for 5 minutes. Supernatant was discarded 
and cells resuspended in 1x annexin-binding buffer. About 5 µl of Alexa Fluor 
488 annexin V and 1 µl of 100 µg/ml PI solution were added to each 100 µl of 
cell suspension and incubated at room temperature for 30 minutes. Following the 
incubation period, 400 µl of 1X annexin-binding buffer was added, this was 
mixed gently and kept on ice. Samples were immediately analysed using the BD 
Accuri flow cytometer by measuring fluorescence emission at 530nm.  
2.2.11 Glycolysis and OXPHOS assays 
Oxygen consumption and Glycolysis measurements were performed following 
the treatments with drugs (LPS, PmB, DCA and MP) in order to measure the 
degree of the reversal of the Warburg effect displayed by the THP-1 cancer cells. 
The Cayman’s oxygen consumption /Glycolysis dual assay kit is a multi-meter 
approach used to measure cellular oxygen consumption and glycolysis in living 
cells. MitoXpress Xtra is used to measure oxygen concentration rate while 
extracellular lactate is quantified as an indication of glycolysis. The kit was used 
for measuring the effect of drugs that modulates the cell metabolism. 
OXPHOS assay 
THP-1 cells were treated at various concentrations of (LPS, MP, DCA and PmB) 
at concentrations mentioned above. 100µl of cells were seeded at a density of 
65000 cells/well in a black, clear bottom 96-well tissue culture treated plate. The 
cells were incubated at 37ºC at 5% CO2 concentration for 24 hours. After 24 
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hours of incubation, 50µl of cells (65 000 cells/well) was added to each well to 
obtain a total volume of 150 µl per well. 10 µl of each drug (LPS, MP, DCA and 
PmB) was transferred to each well and 10µl of MitoXpress Xtra solution added. 
A blank (containing medium only) served as a control for this assay. The wells 
were overlaid with 100µl of pre-warmed HS Mineral oil and plate was read 
kinetically for ≥ 120 minutes on a plate reader.  
Glycolysis assay 
This assay was performed with the same samples for oxygen consumption 
measurements performed above but on a new clear 96-well tissue culture treated 
plate. Ninety microliters of the assay buffer was added to each well and 10 µl of 
mixture containing samples transferred to the well.  100 µl of reaction solution 
was then added to all wells and plate incubated on an orbit shaker for 30 minutes 
at room temperature. The absorbance was read at 490nm with a plate reader.  
2.3 Image and statistical analysis 
Image analysis of captured agarose gels were quantified using MyImage analysis 
software tool. Optical densities were exported to Microsoft Excel for 
normalisation. The results of each series of experiments (performed in triplicates) 
were exported to Microsoft excel and the mean values ± standard deviation of the 
mean (SD) calculated. Levels of the statistical significance were also calculated 
using the paired student t-test when comparing two groups. P-values of ≤ 0.05 
were considered significant. 
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CHAPTER 3: RESULTS 
 
3.1 Overview 
In this study, the expression of TLR4 in LPS- induced THP1 cells was 
investigated and it was observed that 5 ng/ml LPS was optimal in inducing the 
expression of TLR4. An overexpression of TLR4 was also observed in untreated 
THP-1 cells which is suggesting constitutive expression. Cell cycle analysis 
showed that treatment with DCA did not have any impact on the cell progression 
of THP-1 cells. However, cell cycle progression was observed in THP-1 cells 
treated with exogenous MP.  Further analysis of cell death showed that MP and 
DCA treated cells resulted to very minimal apoptotic cell death and decrease in 
necrosis compared to untreated and LPS-treated cells. This suggests that the 2 
drugs cause cell death via apoptosis. In contrary, LPS-treated THP-1 cells showed 
an increase in necrotic cells compared to untreated and other treatments. Also, it 
was observed that treatment with MP and DCA boosted OXPHOS pathway, while 
exogenous MP reduced glycolysis suggesting that this drug indeed reversed 
metabolic reprogramming in THP-1 cells. However, endogenous DCA did not 
show any reduction in glycolysis. Furthermore, LPS treated cells did not show an 
increase in glycolysis, meaning the expected “double” Warburg effect was not 
observed. 
 
3.2 Expression of TLR 4 in THP-1 cells using RT-PCR  
To ascertain the optimal concentration of LPS to induce expression of TLR-4 in 
THP-1 cells, RT-PCR was performed. Cells were seeded and then treated at 5 
ng/ml, 10 ng/ml and 20 ng/ml LPS concentrations for 24 hours and total RNA was 
extracted and RT-PCR was performed. The differential expression of TLR 4 was 
observed at various concentrations of LPS (Figure 3.1). THP-1 cells serve as both 
innate immune and cancer cell-line. LPS is a component that is found on the cell 
wall of gram negative bacteria and it was used in this study to mimic the bacterial 
infection in cancer.  
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When THP-1 cells were treated with 5 ng/ml of LPS, TLR 4 was observed to be 
the most over-expressed compared to at 10 ng/ml and 20 ng/ml. These results 
show that 5 ng/ml of LPS is optimal for the induction of TLR 4 expression. This 
concentration was used for downstream experiments. These results also show that 
indeed LPS is an agonist for TLR 4.  
 
 
 
Figure 3.1: TLR 4 expression in untreated and LPS-stimulated THP-1 cells a) 
Agarose gel electrophoresis showing mRNA expression levels in LPS (5, 10, 20 ng/ml) 
induced THP-1 cells. (b) Densitometry results of mRNA levels at various treatment 
concentrations.  
 
3.3 Cell cycle analysis of THP-1 human monocytic cells following 
various treatments in a time-dependant analyses. 
To determine the cell cycle changes following various treatments, flow cytometry 
was performed. THP-1 cells were treated with 0.08% MP and 10mM DCA and 
combination with 5 ng/ml LPS and 10 µg/ml PmB. Following treatments, cells 
were harvested at different intervals of (6,12,18 and 24 hours). Treatment with 
MP seems to promote cells cycle progression at G2/M phase after 24 hours of 
treatment at about 11.4%, which is about 3 times to that observed for DCA and 
other treatments. This cell cycle progression was only observed in MP-treated 
cells across all time-intervals. Experiments were done in triplicates. Figure 3.2 
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show time-dependant cell cycle phases at 6,12,18 and 24-hour intervals following 
treatments with 5ng/ml LPS, 10mM DCA, 10 µg/ml PmB, and 0.08% of MP. 
 
6 hours 12 hours        18 hours       24 hours  
 Untreated 
 LPS 
MP 
 DCA 
 PMB 
 LPS+MP 
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 LPS+DCA 
6 hours 12 hours        18 hours       24 hours  
 LPS+PMB 
 LPS+MP+PMB 
LPS+DCA+PmB 
Figure 3.2: The effects of various drugs treatments on the cell cycle progression in 
THP-1 cells at various time intervals (6, 12,18, and 24 hours). As shown, cells in the 
Sub-G0 phase (red) represent apoptotic and necrotic THP-1 cells.  5 ng/ml LPS 
(Lipopolysaccharides), 10 mM DCA (Dichloroacetate), 0.08 % MP (Methyl pyruvate), 10 
µg/ml PmB (Polymyxin B). The cell cycle assay was performed using BD Acurri TM flow 
cytometer. The data represented here is a representative of three separate experiments.  
 
At 6, 12,18 and 24 hours of treatment, LPS has no influence on the cell cycle, 
cells seem to stay at G0 with little progression to G2/M. Reversal of the Warburg 
effect with drugs also has no effect on cell cycle. At G0/G1, it does not matter 
what treatment is used on THP-1 cells, it does not change. S phase seems to be 
downregulated in most treatments. Across all treatments, there is a progressive 
decline of the S phase (cells undergoing DNA replication). Even in the presence 
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of drugs (MP and DCA), which are involved in the disruption of metabolic 
reprogramming, these drugs still do not influence the cell cycle of LPS. From all 
these observations, MP alone seems to be the only drug that has any influence in 
the cell cycle of THP-1 cells as oppose to DCA, MP does not reverse progression. 
This drug does not change the proliferative state of the cells. PmB (which 
neutralises LPS) also has no effect on the cell cycle even at 24 hours (Figure 3.6). 
3.3.1 Distribution of cells in sub G0/G1 phase after treatment 
From the cell cycle results, sub-G0 cells from Figure 3.2 indicate cell death, this 
cell cycle phase is easily distinguishable from other phases because cells in this 
phase are characterized by DNA that is less than 2n. After 6, 12 and 18 hours of 
treatment (Figure 3.3,3.4 and 3.5 respectively), it was observed that all the 
treatments had no effect on the proliferative state of the cells. Exogenous MP and 
endogenous DCA show the highest death at sub-G0 with 7.4 and 7.5% 
respectively, following 18 hours of treatment. When cells were treated with a 
combination of LPS and DCA at 24 hours, 9.1% of cells were observed in the 
sub-G0 phase. Interestingly, after 24 hours of treatment with MP alone, 9.1% of 
cells were in the sub-G0 phase. These results are not surprising, because these 
drugs target the metabolism of cancer cells but they do not cause any DNA 
damage to the cells therefore, not many cells were observed in the sub G0/G1 
phase.  
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Figure 3.3: Cell cycle analysis in THP-1 human monocytic cells. Cells were treated 
with 10ng/ml of LPS, 0.08 MP, 10mM DCA and/or 10µg/ml PmB for 6 hours. Data is 
represented as mean ± SD from 3 independent experiments (* indicates p <0.05, ** 
indicates p <0.01, *** indicates p <0.001. 
 
Figure 3.4: Cell cycle analysis in THP-1 human monocytic cells. Cells were treated 
with 10ng/ml of LPS, 0.08 MP, 10mM DCA and/or 10ng/ml PmB for 12 hours. Data is 
represented as mean ± SD from 3 independent experiments (* indicates p <0.05, ** 
indicates p <0.01, *** indicates p <0.001). 
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Figure 3.5: Cell cycle analysis in THP-1 human monocytic cells. Cells were treated 
with 10ng/ml of LPS, 0.08 MP, 10mM DCA and/or 10µg/ml PmB for 18 hours. Data is 
represented as mean ± SD from 3 independent experiments (* indicates p <0.05, ** 
indicates p <0.01, *** indicates p <0.001). 
 
Figure 3.6: Cell cycle analysis in THP-1 human monocytic cells. Cells were treated 
with 10ng/ml of LPS, 0.08 MP, 10mM DCA and/or 10µg/ml PmB for 12 hours. Data is 
represented as mean ± SD from 3 independent experiments (* indicates p <0.05, ** 
indicates p <0.01, *** indicates p <0.001). 
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3.4 Apoptosis induction following various treatments. 
To show whether the observed death was due to apoptosis or necrosis, flow 
cytometry assay was used. This was achieved by using Annexin V and PI staining 
which makes it possible to distinguish between cells that are undergoing apoptosis 
(early and late) and necrotic cells. In this study, cells were treated with the various 
drugs for 24 hours and the cell death observed was analysed to be either via 
apoptosis and necrosis. 
The phosphatidyl serine (PS) of normal cells is located on the cytoplasmic surface 
of the cell membrane. But in apoptotic cells, PS becomes exposed to the external 
environment. Annexin V binds to this PS therefore one can distinguish between 
apoptotic and necrotic cells. PI is a nucleic acid binding dye. This dye does not 
stain live cells or apoptotic cells, but it only stains dead cells, and binds to the 
nucleic acid in the cell. Flow cytometer system is used to distinguish between 
these different populations. Results show percentages of apoptotic and necrotic 
cell death (Figure 3.7). 
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Figure 3.7: Effects of various treatments on inducing apoptosis in THP-1 cells 
following 24 hours of treatment. Each diagram represent a treatment. Annexin V/PI 
stained THP-1 cells following treatment with either 5 ng/ml LPS, 0.08% MP, 10mM 
DCA,10 µg/ml PmB and combination of these treatments in comparison with untreated 
cells for 24 hours. Each of the quadrants represents populations of viable (lower left), 
early apoptotic (lower right), late apoptotic (upper right) and necrotic (upper left) cells.  
 
Results show that induction of apoptosis using drugs such as MP and DCA THP-1 
cells was fairly low (9.2 % and 4.9% respectively) compared to untreated cells 
(2.4%) (Figure 3.8). On the other hand, cell death by necrosis was only 1.3% and 
0.4% for MP and DCA treated cells respectively. This suggests that cell death 
during treatment with DCA is mostly by apoptosis. However, it was onbserved 
from figure 3.8 that treatment of THP-1 cells with exogenous MP alone promotes 
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both apoptosis and necrosis. When cells were treated with LPS, cell death was due 
to necrosis and not apoptosis with about 2.1% necrotic cell death compared to 
0.8% observed in untreated. This suggests that during infection, there is an 
increase in necrotic cell death. Necrosis in tumours have been observed to result 
to poor prognosis. Only (6.5% and 5.5%) increase in apoptosis was observed in 
THP-1 cells treated with LPS and MP or DCA respectively. Cells treated with 
LPS and PmB showed similar results to those observed in untreated THP-1 cells. 
This is not surprising as, PmB blocks the activity of LPS therefore results will 
resemble those of untreated cells (control). 
   a     b 
 
Figure 3.8: Statistical analysis of flow cytometry results-obtained a) apoptosis and b) 
necrosis (%) in THP-1 cells following 24 hours of treatment. T-test was used to 
generate the p-values which compared the difference between the untreated and treated 
scores. Data is represented as mean ± SD from 3 independent experiments (* indicates p 
<0.05, ** indicates p <0.01, *** indicates p <0.001).  
 
3.5 Glycolysis and OXPHOS assays following treatment with drugs 
that reverse the Warburg effect.  
The glycolysis and OXPHOS assays were performed to measure the effect of the 
drugs (MP and DCA) on the metabolism of THP-1 cells following 24 hours of 
treatments. Exogenous MP is known to reverse the metabolism of cancer cells by 
avoiding the glycolytic pathway and thus may shift the metabolism to OXPHOS. 
DCA on the other hand, acts endogenously by inhibiting an enzyme called PDK, 
which (in its active form) phosphorylates PDH and renders it inactive therefore 
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more pyruvate is converted into lactate as oppose to entering the TCA cycle and 
then OXPHOS. In this section, we measured the effect of drugs in the reversal of 
the Warburg effect. The following results were obtained by measuring each 
pathway independently following various treatments (Figure 3.9-3.10).  
Cells treated with MP showed reduced levels of glycolysis as compared to the 
untreated cells (Figure 3.9) while showing an increase in OXPHOS pathway 
(Figure 3.10) suggesting a shift from glycolysis to OXPHOS. Interestingly, MP-
treated cells have the highest rate of OXPHOS compared to the untreated and all 
the other treatments. Exogenous pyruvate boosts OXPHOS as it directly goes to 
the TCA, thereby interfering with the Warburg effect (Monchusi and Ntwasa, 
2017). Furthermore, THP-1 cells treated with DCA showed more dependence on 
OXPHOS as compared to the untreated cells indicating that DCA was able to 
inhibit the enzyme PDK and thereby enabling some pyruvate to be converted into 
the TCA cycle. DCA -treated cells, in contrary to MP-treated THP-1 cells still 
showed some dependence on the glycolytic pathway. DCA inhibits PDK and 
enhances the conversion of pyruvate into the TCA cycle, however, this drug acts 
endogenously, suggesting some of the pyruvate can still be converted into lactate 
as proven by the increased levels of L-lactate concentration in DCA-treated THP-
1 cells. Even in the presence of LPS which mimics infection, therefore 
aggravating the Warburg effect, MP still boosted OXPHOS compared to untreated 
cells. LPS treated cells showed more dependence on the glycolytic pathway and 
less dependence on OXPHOS. This was expected because it is known that upon 
infection, innate immune cells reprogram their metabolism in a manner that is 
similar to the one observed in cancer cells (Warburg effect), and THP-1 cells are 
both innate immune and cancer cells therefore they should display an increased 
Warburg effect. THP-1 cells treated with LPS+DCA showed similar results as 
those observed in DCA only treated cells, whereby cells show slightly more 
dependence on OXPHOS but also promotes the use of the glycolysis pathway 
still. PmB treatments did not show any significant changes when compared to the 
untreated cells. But PmB was only used to block the effect of LPS (a component 
found on the outer layer of gram negative bacteria) since PmB is an antibiotic 
therefore kills gram negative bacteria.   
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Figure 3.9 Glycolysis was analysed in THP-1 cells using the Cayman’s dual assay kit 
system which relies on measurement of lactate (indication of the glycolytic activity) 
in 96 well plates following various treatments for 24 hours. These values were 
exported from the plate reader and exported to excel for analysis. Data is represented as 
mean ± SD from 3 independent experiments (* indicates p <0.05, ** indicates p <0.01, 
*** indicates p <0.001). 
 
Figure 3.10: OXPHOS was analysed in THP-1 cells using the Cayman’s dual assay 
kit system which relies on measurement of quenched oxygen (indication of 
OXPHOS activity) in 96 well plates following various treatments for 24 hours. The 
values were exported from the plate reader and exported to excel for analysis. Data is 
represented as mean ± SD from 3 independent experiments (* indicates p <0.05, ** 
indicates p <0.01, *** indicates p <0.001). 
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CHAPTER 4: DISCUSSION 
 
This study sought to investigate the molecular basis of metabolic reprogramming 
in innate immune cells. The role of exogenous MP in reversing the Warburg effect 
in cancer cells and the effect thereof was also observed. This study has shown that 
by bypassing the glycolytic pathway using drugs such as MP, you subsequently 
promote OXPHOS while suppressing glycolysis. Since cancer cells rely on the 
glycolytic pathway for energy generation (Warburg effect), drugs such as MP and 
DCA that disrupt the Warburg effect resulted in death by apoptosis (although very 
minimal). Surprisingly when endogenous DCA was used to treat cells, it did not 
result to decreased levels of glycolysis. 
Flow cytometry analysis showed that the percentage of apoptotic THP-1 cells 
following treatment with MP and DCA was fairly low. Cancer cells avoid the 
OXPHOS pathway as it is detrimental to them. For example, the production of 
ROS which is a consequence of this pathway leads to toxicity. 
Also, LPS-treated THP-1 cells show an increase in necrosis. Necrosis in tumours 
have been observed to indicate migration and even metastasis. This observation 
may indicate that infected cancer cells might be more aggressive. 
 
4.1. TLR 4 is overexpressed in untreated THP-1 cells compared to the 
LPS-treated cells.  
Innate immune response to stimuli such as LPS, a TLR 4 agonist, triggers a 
variety of cellular responses that may have positive or negative effects on cellular 
activation downstream. In this study, the expression of TLR4 was investigated in 
untreated and LPS-treated THP-1 cells. THP-1 cells were cultured at a density of 
2 x 105 cells/ml and incubated without and with different LPS concentrations (5, 
10 & 20 ng/ml) for 24 hours. Total RNA was extracted and analysed for TLR4 
expression using RT-PCR. It was observed that the expression of TLR4 in 
untreated THP-1 cells were overexpressed compared to the LPS-treated cells 
across all concentrations (Figure 3.1). This indicates that TLR4 is constitutively 
expressed in THP-1 cells. This is important for the study because THP-1 cells 
43 
 
were specifically chosen for this project as they are both innate immune and 
cancer cells. Upon stimulation by agonist such as LPS, innate immune cells 
reprogram their metabolism by displaying more dependence on glycolysis and 
reduced levels of OXPHOS – this is called the Warburg effect. Toll-like receptors 
(TLRs) are type I transmembrane proteins that have a leucine-rich repeat 
extracellular domain as well as a conserved Toll/Interleukin-1 (TIR) receptor 
domain in the cytoplasmic region (O’Neill et al., 2003; Takeda and Akira, 2005). 
They are well known for their role in host defence against pathogens by 
recognising pathogen-associated molecular patterns (PAMPs) which are 
conserved molecular signatures (such as LPS) expressed by microbial pathogens 
(Henneke and Golenbock, 2002; Takeda et al., 2002). Lipopolysaccharide is a 
component of the Gram-negative bacterial cell wall. In this study, LPS was used 
to mimic bacterial infection and it was observed that TLR 4 was also highly 
expressed at 5 ng/ml compared to other concentrations. This observation is 
consistent with the role of TLR4 in recognizing and defending cells against 
pathogens. Studies have shown that TLR mRNAs are strongly responsive to a 
variety of stimuli including infection, however, their expression may be 
significantly affected when activated by other TLR agonists (Flo et al., 2001; Liu 
et al., 2000). Another study showed that endotoxin protein-depleted LPS further 
increased the expression of many TLR mRNAs either than TLR 4. Interestingly, 
studies by Hirschifeld et al., 2006 also showed that pre-treatment of THP-1 cells 
with PMA up-regulates the expression of TLR8 up to about 5-fold. TLR 8 
expression has been shown to be further up-regulated by LPS to a final expression 
level 50 times that of untreated undifferentiated THP-1 cells and this may also 
explain the observed enhanced TLR 4 expression in untreated THP-1 cells. This 
may suggest that differentiating monocytes into macrophages might play a role in 
the level of TLR expression, therefore pre-treatment of THP-1 cells with PMA 
prior to treatment with LPS may have increased the expression of TLR4 during 
treatment with LPS compared to untreated cells.  
This study has confirmed the expression of TLR4 in untreated THP-1 cells and 
LPS-treated cells, corroborating its role in immune defence.  
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4.2 Introduction of exogenous pyruvate or augmenting endogenous 
pyruvate induces apoptosis  
It was expected that the THP-1 cells would be glycolytic since they are 
transformed cells. The impact of reversing the Warburg effect on cell proliferation 
was then tested. Thus, the cell cycle and the apoptotic effects of MP and DCA, 
were investigated in THP-1 cells. The cells were treated with various drugs in a 
time dependent manner and subsequently analysed using a flow cytometer. Cell 
cycle analysis revealed that treatment with MP resulted in an increase in cells at 
the Sub-G0 phase (Figure 3.2-3.6). This phase represents cells with fragmented 
DNA, which is a characteristic of cells undergoing apoptosis. This makes sense as 
MP and DCA target the unique cancer metabolism disrupting it therefore killing 
cells.  
Apoptotic cell death was further measured by staining with Annexin V/PI stains 
(Figures 3.7 and 3.8). This study observed that when cells were treated with MP, 
only 8.0% increase in apoptosis was observed in comparison to untreated cells at 
only 2%.  
DCA-treated cells also showed only 3.9% in apoptosis when compared to the 
untreated cells. DCA has been in use as a drug for treatment of lactic acidosis for 
decades and therefore details of the drug’s pharmacokinetics and toxicity profile 
have been well studied (Stacpoole et al., 1998). The studies by Bonnet et al 
(2007) showed that DCA has selective killing mechanisms that allows it to 
specifically target cancer cells and not normal cells. These selective mechanisms 
of inducing apoptosis include: depolarization of the mitochondrial membrane, 
suppression of glycolysis, production of reactive oxygen species, induction of the 
plasma membrane potassium channel, and release of pro-apoptotic factors from 
mitochondria. Wong et al (2008) showed that dichloroacetate caused apoptosis in 
endometrial cancer cells, while Cao et al (2008) showed that the DCA sensitized 
prostate cancer cells to radiation.  In this study, 10 mM DCA was used to treat 
THP-1 cells and apoptosis was observed although only slightly. The slight 
apoptosis observed might be due to the concentration used as other studies have 
shown that a higher concentration of DCA (≥25 mM) induced increased apoptosis 
(Stockwin et al., 2010; Madhok et al., 2010; Xiao et al., 2010; Heshe et al., 2010; 
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Sun et al., 2010). These findings suggest that by blocking the activity of pyruvate 
dehydrogenase kinase, leads to the activation of pyruvate dehydrogenase. DCA 
might be responsible for some of the observed apoptosis induction in THP-1 cells. 
Furthermore, most studies done utilized other cancer cell lines not THP-1 cells, 
thus the apoptotic effect of DCA might also be cancer specific. Other studies have 
also used DCA in combination with drugs such as Paclitaxel, therefore the effects 
of DCA as a sole drug might not have a significant effect in inducing apoptosis. 
In this study, MP was found to be a better agent in inducing apoptosis of THP-1 
cells even after stimulation of the TLR-4 signalling pathway by LPS as compared 
to DCA. Future studies using increased concentrations of DCA may prove 
important. Targeting the metabolism of cancer cells seem to be effective as shown 
in this study using MP. 
 
4.3 Exogenous and endogenous pyruvate reverse the metabolic 
reprogramming in THP-1 cells (Warburg effect) 
This study evaluated the impact of exogenous pyruvate and DCA on the metabolic 
programme of THP-1 cells. Furthermore, to establish the nature of the role played 
by TLR4. Cells were cultured in 96 well plates under previously mentioned 
conditions, and treated with different treatments for 24 hours. Cayman’s dual 
assay (measures glycolysis and OXPHOS) kit was used to measure the metabolic 
pathways. It was established that THP-1 cells are already glycolytic. This study 
showed that introduction of exogenous MP reverses the Warburg effect by 
boosting OXPHOS even in the presence of LPS (stimulates TLR4) which 
according to literature, worsens the Warburg effect. In the first instance, this 
present study established that THP-1 cells were already glycolytic because 
glycolysis is elevated in untreated cells. Treatment of THP-1 cells with exogenous 
MP shifted the metabolism of cancer cells as it leads to significantly reduced 
glycolysis and higher OXPHOS (Figure 3.9-3.10).  These findings suggest that 
exogenous MP indeed reverses the Warburg effect corroborating and confirming 
the hypothesis of a recent study by Monchusi and Ntwasa, 2017 that showed that 
exogenous MP kills cancer cells by evading the glycolytic pathway. MP is a 
lipophilic membrane permeable agent and when introduced exogenously it goes 
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directly into the TCA cycle, thereby boosting OXPHOS by inhibiting the Warburg 
effect (Lembert et al., 2001). This study also observed no change in glycolysis 
and a slight increase in OXPHOS activity when THP-1 cells were treated with 
DCA (Figure 3.9, 3.10) indicating its role in reverse metabolic reprogramming. 
Endogenous DCA is an inhibitor of pyruvate dehydrogenase kinase (PDK), an 
enzyme that inhibits pyruvate dehydrogenase (PDH) which is responsible for 
catalysing the conversion of pyruvate into Acetyl CoA, which enters the 
tricarboxylic acid (TCA) cycle, and subsequently into OXPHOS. When PDK is 
active, it phosphorylates PDH, rendering it inactive and thus, reduces the entry of 
pyruvate into the TCA cycle. PDK plays an important role in promoting 
glycolysis and reducing levels of OXPHOS. Therefore, DCA inhibits PDK and 
consequently reduces glycolysis by boosting OXPHOS. However, in this study 
DCA did not reduce glycolysis but was able to increase OXPHOS, this may 
suggest that some of the pyruvate was still converted into lactate thus the increase 
in glycolysis (DCA acts endogenously). This study also mimicked infection in 
THP-1 cells by treatment with LPS. LPS treated cells did not show aggravated 
Warburg effect, since upon infection, innate immune cells rewire their metabolism 
in a manner similar to that observed in cancer cells. Treatment with MP and DCA 
boosted the OXPHOS pathway in LPS-treated cells further confirming their roles 
in reversing the Warburg effect 
Although these drugs use different mechanisms, they both seem to target the 
metabolic program by either reducing glycolysis and/or increasing OXPHOS. 
Therefore, they might serve as possible therapeutic agents for cancer treatment.   
 
4.4 Conclusion 
Cancer cells prefer the less efficient glycolytic pathway (Warburg effect) as a 
source of energy production to enable proliferation. This preference is also 
observed during infection. This study has shown that indeed treatment with drugs 
such as MP and DCA drugs reprogram the metabolism of THP-1 cells resulting in 
cell death via apoptosis. Importantly, this study has observed that MP treatment 
was able to cause cell death by boosting OXPHOS and inhibiting the glycolytic 
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pathway. Taken together, targeting the energy metabolism of cancer cells provides 
a promising avenue for cancer therapy. 
 
4.5 Future studies 
Future studies corroborating the results observed in this study in in vivo models is 
crucial. Additionally, experiments comparing the effect of drugs such as MP and 
DCA in different cell lines should be performed. Furthermore, the molecular 
mechanisms involved in linking infection with cancer should also be investigated 
in various cell lines. Importantly, in vivo studies further confirming the effects of 
these drugs should be done. 
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APPENDIX A: CHEMICALS AND REAGENTS 
Table A1: The following chemical and reagents were used in the study. 
Chemical/Reagent Supplier Catalogue no. 
RPMI Sigma 13924 
Penicillin/Streptomycin Sigma P4333 
Fetal bovine serum 
(FBS) 
Biowest S181G 
Dimethyl sulfoxide Sigma D8418 
Lipopolysaccharide Sigma L3024 
Sodium Dichloroacetate Sigma 347795 
Methyl pyruvate Sigma 37, 117-3 
Polymyxin B Sigma T3424-25ML 
TRIzol Sigma C-2432 
Chloroform Sigma 1036573 
Isopropanol MERCK UN 1170 
Ethanol absolute VWR chemicals 20821.330 
Nuclease free water QIAGEN 129117 
Ethidium Bromide Sigma-Aldrich 1239-45-8 
Agarose powder White Sci. 50004 
1 kb Plus DNA ladder 
(0.1 µg/µl) 
Thermo Scientific SM1333 
6X DNA loading dye Thermo Scientific R0611 
Glycerol MERCK 2676500LC 
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APPENDIX B: LABORATORY EQUIPMENT 
Table A2: The following laboratory equipment was used in this study. 
Equipment  Supplier and model no. 
Vortex Scientific industries 
43178 
Heating block Labnet 
D1100-230V 
GeneAmp PCR machine Perkin Elmer 
2400 
Water bath Julabo P 
130 
Microscope Olympus 
SZ40 
Microwave oven KIC  
MWS- 900M 
Weighing balance Precisa  
XT220A 
Labelling system Bio-Rad 
XR+ 
Orbit shaker  LAB-LINE 
3521 3522-1 
Nano-drop 
spectrophotometer 
Thermo-Fischer Scientific USA 
1000 
Electrophoresis power 
supply 
Bio-Rad 
3000Xi 
BD Accuri TM C6 
cytometer 
Biosciences 
BD Accuri C6+ 
4ºC Refrigerator KIC 
KBF 634/WH 
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APPENDIX C: KITS 
Table A3: The following kits were used in this study. 
Product name Supplier Catalogue number 
ProtoScript first strand 
cDNA synthesis kit  
BioLabs Inc E6300S; 0041411 
Taq 2x Master mix kit BioLabs Inc M0270L; 0231412 
Apoptosis kit Thermo Scientific BM 500FI-100 
Cell cycle kit Thermo Scientic F10797 
Oxygen 
Consumption/Glycolysis 
Dual assay kit 
Cayman 601060 
 
 
APPENDIX D: BUFFERS 
Table A4: The following buffers and composition were used in this study. 
Buffer Composition 
TAE buffer 
 
40mM Tris 
20mM Acetic acid 
1mM EDTA 
Citric saline buffer 10X 1.35 M KCL 
0.15 M sodium azide 
Phosphate buffered saline  Sigma (tablets) 
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APPENDIX E: CELL CYCLE RAW DATA GENERATED USING BD 
ACCURI 
Cell cycle 
Plot 4: A02 Untreated stained: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,47% 
S phase (499,405.0 / 702,381.0) 18,04% 
G2/M (702,382.0 / 944,643.0) 19,31% 
Dead  (100,000.0 / 302,975.0) 4,46% 
    
Plot 4: A03 Untreated stained 2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 51,39% 
S phase (499,405.0 / 702,381.0) 18,89% 
G2/M (702,382.0 / 944,643.0) 19,41% 
Dead  (100,000.0 / 302,975.0) 5,32% 
    
Plot 4: A04 Untreated stained 3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,09% 
S phase (499,405.0 / 702,381.0) 17,90% 
G2/M (702,382.0 / 944,643.0) 18,85% 
Dead  (100,000.0 / 302,975.0) 4,82% 
    
Plot 4: A05 LPS1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,21% 
S phase (499,405.0 / 702,381.0) 20,35% 
G2/M (702,382.0 / 944,643.0) 14,22% 
Dead  (100,000.0 / 302,975.0) 8,33% 
    
Plot 4: A06 LPS2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,51% 
S phase (499,405.0 / 702,381.0) 18,59% 
G2/M (702,382.0 / 944,643.0) 19,12% 
Dead  (100,000.0 / 302,975.0) 4,01% 
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Plot 4: A07 LPS3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,25% 
S phase (499,405.0 / 702,381.0) 19,76% 
G2/M (702,382.0 / 944,643.0) 18,44% 
Dead  (100,000.0 / 302,975.0) 4,53% 
    
Plot 4: A08 MP1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,93% 
S phase (499,405.0 / 702,381.0) 19,21% 
G2/M (702,382.0 / 944,643.0) 16,71% 
Dead  (100,000.0 / 302,975.0) 5,53% 
    
Plot 4: A09 MP2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 54,37% 
S phase (499,405.0 / 702,381.0) 19,84% 
G2/M (702,382.0 / 944,643.0) 17,51% 
Dead  (100,000.0 / 302,975.0) 3,89% 
    
Plot 4: A10 MP3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,86% 
S phase (499,405.0 / 702,381.0) 17,99% 
G2/M (702,382.0 / 944,643.0) 16,52% 
Dead  (100,000.0 / 302,975.0) 5,62% 
    
Plot 4: A11 DCA1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,52% 
S phase (499,405.0 / 702,381.0) 19,23% 
G2/M (702,382.0 / 944,643.0) 18,14% 
Dead  (100,000.0 / 302,975.0) 5,48% 
    
Plot 4: A12 DCA2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,36% 
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S phase (499,405.0 / 702,381.0) 19,68% 
G2/M (702,382.0 / 944,643.0) 13,53% 
Dead  (100,000.0 / 302,975.0) 8,63% 
    
Plot 4: B01 DCA3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,47% 
S phase (499,405.0 / 702,381.0) 19,39% 
G2/M (702,382.0 / 944,643.0) 18,56% 
Dead  (100,000.0 / 302,975.0) 4,32% 
    
Plot 4: B02 PmB1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 54,51% 
S phase (499,405.0 / 702,381.0) 20,78% 
G2/M (702,382.0 / 944,643.0) 14,48% 
Dead  (100,000.0 / 302,975.0) 5,39% 
    
Plot 4: B03 PmB2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 55,36% 
S phase (499,405.0 / 702,381.0) 19,59% 
G2/M (702,382.0 / 944,643.0) 15,08% 
Dead  (100,000.0 / 302,975.0) 4,96% 
    
Plot 4: B04 PmB3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 55,39% 
S phase (499,405.0 / 702,381.0) 19,28% 
G2/M (702,382.0 / 944,643.0) 15,34% 
Dead  (100,000.0 / 302,975.0) 4,53% 
    
Plot 4: B05 LPS +MP1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 51,91% 
S phase (499,405.0 / 702,381.0) 19,47% 
G2/M (702,382.0 / 944,643.0) 17,25% 
Dead  (100,000.0 / 302,975.0) 4,58% 
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Plot 4: B06 LPS +MP2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,02% 
S phase (499,405.0 / 702,381.0) 19,48% 
G2/M (702,382.0 / 944,643.0) 15,45% 
Dead  (100,000.0 / 302,975.0) 4,85% 
    
Plot 4: B07 LPS +MP3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,62% 
S phase (499,405.0 / 702,381.0) 18,23% 
G2/M (702,382.0 / 944,643.0) 14,22% 
Dead  (100,000.0 / 302,975.0) 5,55% 
    
Plot 4: B08 LPS +DCA1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 50,16% 
S phase (499,405.0 / 702,381.0) 18,78% 
G2/M (702,382.0 / 944,643.0) 20,33% 
Dead  (100,000.0 / 302,975.0) 4,16% 
    
Plot 4: B09 LPS +DCA2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 48,86% 
S phase (499,405.0 / 702,381.0) 17,91% 
G2/M (702,382.0 / 944,643.0) 18,79% 
Dead  (100,000.0 / 302,975.0) 4,56% 
    
Plot 4: B10 LPS +DCA3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 48,05% 
S phase (499,405.0 / 702,381.0) 19,57% 
G2/M (702,382.0 / 944,643.0) 20,95% 
Dead  (100,000.0 / 302,975.0) 4,82% 
    
Plot 4: B11 LPS +PmB 1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
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G0/G1 (296,429.0 / 499,404.0) 52,44% 
S phase (499,405.0 / 702,381.0) 25,40% 
G2/M (702,382.0 / 944,643.0) 2,88% 
Dead  (100,000.0 / 302,975.0) 17,76% 
    
Plot 4: B12 LPS +PmB2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 55,02% 
S phase (499,405.0 / 702,381.0) 20,15% 
G2/M (702,382.0 / 944,643.0) 16,01% 
Dead  (100,000.0 / 302,975.0) 4,85% 
    
Plot 4: C01 lps+mp+pMb: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 54,11% 
S phase (499,405.0 / 702,381.0) 20,57% 
G2/M (702,382.0 / 944,643.0) 14,39% 
Dead  (100,000.0 / 302,975.0) 3,71% 
    
Plot 4: C02 LPS+MP+PmB 2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 51,64% 
S phase (499,405.0 / 702,381.0) 18,46% 
G2/M (702,382.0 / 944,643.0) 16,82% 
Dead  (100,000.0 / 302,975.0) 4,75% 
    
Plot 4: C03 LPS+DCA+PmB 1: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 53,93% 
S phase (499,405.0 / 702,381.0) 20,50% 
G2/M (702,382.0 / 944,643.0) 15,25% 
Dead  (100,000.0 / 302,975.0) 4,04% 
    
Plot 4: C04 LPS+MP+PmB 3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 52,70% 
S phase (499,405.0 / 702,381.0) 19,16% 
G2/M (702,382.0 / 944,643.0) 15,07% 
Dead  (100,000.0 / 302,975.0) 4,28% 
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Plot 4: C05 LPS+DCA+PmB 2: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 51,85% 
S phase (499,405.0 / 702,381.0) 20,17% 
G2/M (702,382.0 / 944,643.0) 16,07% 
Dead  (100,000.0 / 302,975.0) 4,78% 
    
Plot 4: C06 LPS+DCA+PmB 3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 50,88% 
S phase (499,405.0 / 702,381.0) 17,92% 
G2/M (702,382.0 / 944,643.0) 17,43% 
Dead  (100,000.0 / 302,975.0) 5,84% 
    
Plot 4: C07 IR8mM: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 65,31% 
S phase (499,405.0 / 702,381.0) 11,26% 
G2/M (702,382.0 / 944,643.0) 6,45% 
Dead  (100,000.0 / 302,975.0) 13,10% 
    
Plot 4: C12 LPS +PmB3: Gated on (Singlets in all) and (P2 in all) 
% of This 
Plot 
This Plot 100,00% 
G0/G1 (296,429.0 / 499,404.0) 46,82% 
S phase (499,405.0 / 702,381.0) 21,98% 
G2/M (702,382.0 / 944,643.0) 18,41% 
Dead  (100,000.0 / 302,975.0) 6,07% 
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APPENDIX F: FLOW CYTOMETRY OBTAINED APOPTOSIS 
RESULTS, FOLLOWING VARIOUS TREATMENTS 
Apoptosis 
Plot 2: A01 Untreated UNstained: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,03% 
Late Apop 0,00% 
Live cells 99,97% 
Early Apop 0,00% 
    
Plot 2: A02  Annexin V only: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,03% 
Late Apop 0,18% 
Live cells 97,27% 
Early Apop 2,52% 
    
Plot 2: A03 PI only: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 2,76% 
Late Apop 0,00% 
Live cells 97,24% 
Early Apop 0,00% 
    
Plot 2: A04 untreated stained: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,84% 
Late Apop 2,44% 
Live cells 96,24% 
Early Apop 0,47% 
    
Plot 2: A05 US: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,94% 
Late Apop 2,35% 
Live cells 96,35% 
Early Apop 0,36% 
    
Plot 2: A06 US2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,08% 
Late Apop 2,40% 
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Live cells 96,23% 
Early Apop 0,29% 
    
Plot 2: A07 LPS 1: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,99% 
Late Apop 3,38% 
Live cells 94,28% 
Early Apop 0,35% 
    
Plot 2: A08 LPS 2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 2,09% 
Late Apop 2,73% 
Live cells 94,82% 
Early Apop 0,35% 
    
Plot 2: A09 LPS 3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 2,02% 
Late Apop 2,93% 
Live cells 94,72% 
Early Apop 0,33% 
    
Plot 2: A10 LPS+DCA: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,81% 
Late Apop 4,05% 
Live cells 93,85% 
Early Apop 0,30% 
    
Plot 2: A11 LPS+DCA 2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,15% 
Late Apop 5,24% 
Live cells 93,31% 
Early Apop 0,30% 
    
Plot 2: A12 LPS+DCA 3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,52% 
Late Apop 3,98% 
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Live cells 94,11% 
Early Apop 0,39% 
    
Plot 2: B01 LPS+MP: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,37% 
Late Apop 2,53% 
Live cells 95,72% 
Early Apop 0,38% 
    
Plot 2: B02 LPS+MP2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 2,91% 
Late Apop 6,06% 
Live cells 90,60% 
Early Apop 0,43% 
    
Plot 2: B03 LPS+MP3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,93% 
Late Apop 6,67% 
Live cells 90,76% 
Early Apop 0,65% 
    
Plot 2: B04 LPS+PmB: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,38% 
Late Apop 2,96% 
Live cells 95,34% 
Early Apop 0,33% 
    
Plot 2: B05 LPS+PmB 2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,11% 
Late Apop 5,90% 
Live cells 92,34% 
Early Apop 0,65% 
    
Plot 2: B06 LPS+PmB: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,72% 
Late Apop 2,70% 
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Live cells 96,11% 
Early Apop 0,47% 
    
Plot 2: B07 LPS+PmB+DCA: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,19% 
Late Apop 3,88% 
Live cells 94,53% 
Early Apop 0,39% 
    
Plot 2: B08 LPS+PmB+DCA 2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,50% 
Late Apop 6,13% 
Live cells 91,60% 
Early Apop 0,78% 
    
Plot 2: B09 LPS+PmB+DCA 3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,73% 
Late Apop 3,48% 
Live cells 95,16% 
Early Apop 0,64% 
    
Plot 2: B10 LPS+PmB+MP: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,88% 
Late Apop 3,81% 
Live cells 94,80% 
Early Apop 0,51% 
    
Plot 2: B11 LPS+PmB+MP 2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,47% 
Late Apop 4,93% 
Live cells 92,88% 
Early Apop 0,73% 
    
Plot 2: B12 LPS+PmB+MP 3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,28% 
Late Apop 4,15% 
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Live cells 94,06% 
Early Apop 0,51% 
    
Plot 2: C01 IR 8uM: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 33,35% 
Late Apop 12,22% 
Live cells 52,09% 
Early Apop 2,34% 
    
Plot 2: C02 PmB: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,31% 
Late Apop 2,67% 
Live cells 95,74% 
Early Apop 0,28% 
    
Plot 2: C03 PmB 2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,27% 
Late Apop 2,63% 
Live cells 95,85% 
Early Apop 0,26% 
    
Plot 2: C04 PmB 3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,04% 
Late Apop 2,73% 
Live cells 95,86% 
Early Apop 0,36% 
    
Plot 2: C05 MP: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 2,64% 
Late Apop 6,38% 
Live cells 90,26% 
Early Apop 0,72% 
    
Plot 2: C06 MP2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,32% 
Late Apop 7,99% 
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Live cells 89,52% 
Early Apop 1,17% 
    
Plot 2: C07 MP3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,65% 
Late Apop 6,45% 
Live cells 90,85% 
Early Apop 1,05% 
    
Plot 2: C08 DCA: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,42% 
Late Apop 3,90% 
Live cells 94,72% 
Early Apop 0,96% 
    
Plot 2: C09 DCA2: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 1,09% 
Late Apop 3,23% 
Live cells 95,07% 
Early Apop 0,61% 
    
Plot 2: C10 DCA 3: Gated on (Cells in all) % of This Plot 
This Plot 100,00% 
Necrotic 0,59% 
Late Apop 3,43% 
Live cells 95,55% 
Early Apop 0,44% 
 
 
 
 
 
 
 
 
72 
 
APPENDIX G: GLYCOLYSIS RESULTS AND STANDARD CURVE 
FOLLOWING 24 HOURS OF TREATMENT 
 
 
 
 
Figure A1: Standard curve for the L-Lactate concentrations obtained from 
the L-lactate concentrations (orange) and glycolysis assay treatments (blue).  
The values were generated from the plate reader and exported to excel for 
standard curve generation. 
 
Sample 1 2 3 4 5 6 7
 A Un_0001 1/1 Un_0009 1/1 Un_0017 1/1 Un_0025 1/1 Un_0033 1/1 Un_0041 1/1 Un_0049 1/1
 B Un_0002 1/1 Un_0010 1/1 Un_0018 1/1 Un_0026 1/1 Un_0034 1/1 Un_0042 1/1 Un_0050 1/1
 C Un_0003 1/1 Un_0011 1/1 Un_0019 1/1 Un_0027 1/1
 D Un_0004 1/1 Un_0012 1/1 Un_0020 1/1 Un_0028 1/1
 E Un_0005 1/1 Un_0013 1/1 Un_0021 1/1 Un_0029 1/1
 F Un_0006 1/1 Un_0014 1/1 Un_0022 1/1 Un_0030 1/1
 G Un_0007 1/1 Un_0015 1/1 Un_0023 1/1 Un_0031 1/1
 H Un_0008 1/1 Un_0016 1/1 Un_0024 1/1 Un_0032 1/1
Value 1 2 3 4 5 6 7
 A 1,34749 0,762324 0,757559 0,742162 0,565702 0,687439 0,671598
 B 0,969794 0,689416 0,697977 0,710572 0,627537 0,559661 0,667925
 C 0,634989 0,420753 0,30401 0,420631
 D 0,470702 0,525211 0,526493 0,488633
 E 0,339059 0,576554 0,417065 0,462494
 F 0,227861 0,474873 0,485556 0,483083
 G 0,32476 0,519274 0,709237 0,604653
 H 0,305143 0,628005 0,638235 0,611113
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APPENDIX H: OXPHOS RESULTS FOLLOWING 24 HOURS OF 
TREATMENT 
Sample 1 2 3 4 5 6 7 
 A 
Un_0001 
1/1 
Un_0009 
1/1 
Un_0017 
1/1 
Un_0025 
1/1 
Un_0033 
1/1 
Un_0041 
1/1   
 B 
Un_0002 
1/1 
Un_0010 
1/1 
Un_0018 
1/1 
Un_0026 
1/1 
Un_0034 
1/1 
Un_0042 
1/1   
 C 
Un_0003 
1/1 
Un_0011 
1/1 
Un_0019 
1/1 
Un_0027 
1/1 
Un_0035 
1/1 
Un_0043 
1/1   
 D 
Un_0004 
1/1 
Un_0012 
1/1 
Un_0020 
1/1         
 E 
Un_0005 
1/1 
Un_0013 
1/1 
Un_0021 
1/1         
 F 
Un_0006 
1/1 
Un_0014 
1/1 
Un_0022 
1/1         
 G 
Un_0007 
1/1 
Un_0015 
1/1 
Un_0023 
1/1         
 H 
Un_0008 
1/1 
Un_0016 
1/1 
Un_0024 
1/1 
Un_0032 
1/1 
Un_0040 
1/1 
Un_0048 
1/1 
Un_0056 
1/1 
                
Value 1 2 3 4 5 6 7 
 A 126,184 124,694 120,026 121,404 113,083 118,559   
 B 110,921 123,525 132,809 102,081 103,021 114,38   
 C 127,515 132,707 130,075 115,299 112,946 107,334   
 D 127,085 132,395 141,782         
 E 94,8322 124,022 119,39         
 F 142,093 125,162 117,615         
 G 148,753 187,122 117,667         
 H 1,53055 0,91387 0,87085 110,69 103,315 97,2942 91,0147 
Plate 1: 1, reading 2 
Sample 1 2 3 4 5 6 7 
 A 
Un_0001 
1/1 
Un_0009 
1/1 
Un_0017 
1/1 
Un_0025 
1/1 
Un_0033 
1/1 
Un_0041 
1/1   
 B 
Un_0002 
1/1 
Un_0010 
1/1 
Un_0018 
1/1 
Un_0026 
1/1 
Un_0034 
1/1 
Un_0042 
1/1   
 C 
Un_0003 
1/1 
Un_0011 
1/1 
Un_0019 
1/1 
Un_0027 
1/1 
Un_0035 
1/1 
Un_0043 
1/1   
 D 
Un_0004 
1/1 
Un_0012 
1/1 
Un_0020 
1/1         
 E 
Un_0005 
1/1 
Un_0013 
1/1 
Un_0021 
1/1         
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 F 
Un_0006 
1/1 
Un_0014 
1/1 
Un_0022 
1/1         
 G 
Un_0007 
1/1 
Un_0015 
1/1 
Un_0023 
1/1         
 H 
Un_0008 
1/1 
Un_0016 
1/1 
Un_0024 
1/1 
Un_0032 
1/1 
Un_0040 
1/1 
Un_0048 
1/1 
Un_0056 
1/1 
Value 1 2 3 4 5 6 7 
 A 106,121 111,388 105,627 109,687 101,446 110,285   
 B 98,2672 96,7918 105,3 87,9782 88,1424 99,1632   
 C 112,737 102,999 109,259 100,592 95,4129 96,2257   
 D 113,842 92,4084 120,719         
 E 83,5254 90,0705 108,628         
 F 122,359 104,235 104,34         
 G 130,704 166,306 102,846         
 H 0,58926 1,08193 0,2357 99,3138 100,573 91,5644 85,6803 
 
